NasdaqGM - Nasdaq Real Time Price ? USD Nurix Therapeutics, Inc. (NRIX) Follow Compare 25.05 +0.33 (+1.33%) At close: October 18 at 4:00 PM EDT 25.63 +0.58 (+2.32%) After hours: October 18 at 6:56 PM EDT All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Nurix Therapeutics Presents Positive Results from the Ongoing Clinical Trial of Its BTK Degrader NX-5948 in Patients with Relapsed/Refractory Waldenstrom’s Macroglobulinemia NX-5948 demonstrated robust clinical activity with objective responses observed in 7 of 9 (77.8%) evaluable Waldenstrom’s patients in the ongoing Phase 1a/1b clinical trial Responses are durable and deepen over time with two patients on treatment for greater than one year Data were presented at the 12th International Workshop on Waldenstrom’s Macroglobulinemia (IWWM-12) SAN FRANCISCO, Oct. 19, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical co GlobeNewswire ? yesterday NRIX +1.33% Nurix Therapeutics Expands Its Board of Directors with the Addition of Drug Commercialization Expert Anil Kapur SAN FRANCISCO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced the appointment of Anil Kapur to its board of directors, effective October 15, 2024. Mr. Kapur has over 25 years of executive experience in pharmaceutical and biotech companies across both U.S. and international markets. “I am delighted to GlobeNewswire ? 3 days ago NRIX +1.33% Nurix Therapeutics, Inc. (NRIX) Reports Q3 Loss, Lags Revenue Estimates Nurix Therapeutics (NRIX) delivered earnings and revenue surprises of 0% and 9.11%, respectively, for the quarter ended August 2024. Do the numbers hold clues to what lies ahead for the stock? Zacks ? 8 days ago NRIX +1.33% Nurix Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Provides a Corporate Update Initiated Phase 1b dose expansion of NX-5948 in chronic lymphocytic leukemia patient population with Fast Track Designation from the FDA Initiated Phase 1b dose expansion of NX-5948 in Waldenstrom’s macroglobulinemia, follicular lymphoma and marginal zone lymphoma patients Reinitiated enrollment for NX-2127 in a Phase 1a/b trial in oncology Presented preclinical data on Degrader-Antibody Conjugates (DACs), a new class of therapeutics Well capitalized with cash and marketable securities of $457.5 GlobeNewswire ? 8 days ago NRIX +1.33% Nurix Therapeutics Announces Presentations at ACR Convergence 2024, the Annual Meeting of the American College of Rheumatology SAN FRANCISCO, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that preclinical data will be presented from NX-5948, Nurix’s proprietary BTK degrader currently in Phase 1b development for B-cell malignancies and in IND enabling studies for autoimmune disease, and GS-6791/NX-0479, an IRAK4 degrader disc GlobeNewswire ? 11 days ago NRIX +1.33% Nurix Therapeutics Announces Presentations at?Discovery on Target Conference SAN FRANCISCO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced three oral presentations at the 22nd Annual Discovery on Target conference, being held September 30 – October 3, 2024, in Boston, MA. “The presentations at Discovery on Target highlight Nurix’s ability to repeatedly address difficult-to-dr GlobeNewswire ? 20 days ago NRIX +1.33% Nurix Therapeutics To Participate in Upcoming?ADC & Radiopharmaceuticals Pharma & Biotech Partnering Summit SAN FRANCISCO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Gwenn M. Hansen, Ph.D., chief scientific officer of Nurix, will present an update on Nurix’s Degrader-Antibody Conjugate (DAC) platform at the ADC & Radiopharmaceuticals Pharma & Biotech Partnering Summit being held in Boston from Sep GlobeNewswire ? last month NRIX +1.33% Nurix Therapeutics, Inc. (NRIX): This Small-Cap Healthcare Stock Is A Good Buy Right Now We recently compiled a list of the 10 Best Small-Cap Healthcare Stocks To Buy Now. In this article, we are going to take a look at where Nurix Therapeutics, Inc. (NASDAQ:NRIX) stands against the other small-cap healthcare stocks. Healthcare Sector: A Defensive Investment with Growth Potential in 2024 In difficult economic times, healthcare equities are sometimes […] Insider Monkey ? last month NRIX +1.33% Nurix Therapeutics to Participate in Upcoming Investor Conferences SAN FRANCISCO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Arthur T. Sands, M.D, Ph.D., president and chief executive officer of Nurix, Hans van Houte, chief financial officer of Nurix, and Jason Kantor, Ph.D., chief business officer of Nurix, will participate in the following conferences in S GlobeNewswire ? last month NRIX +1.33% Insider Sale: CFO Houte Van Sells 20,000 Shares of Nurix Therapeutics Inc (NRIX) On August 26, 2024, Houte Van, Chief Financial Officer of Nurix Therapeutics Inc (NASDAQ:NRIX), sold 20,000 shares of the company at a price of $25.22 per share. GuruFocus.com ? last month NRIX +1.33% We're Not Very Worried About Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Rate Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... Simply Wall St. ? 2 months ago NRIX +1.33% How Much Upside is Left in Nurix Therapeutics (NRIX)? Wall Street Analysts Think 25.27% The mean of analysts' price targets for Nurix Therapeutics (NRIX) points to a 25.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. Zacks ? 2 months ago NRIX +1.33% Are You Looking for a Top Momentum Pick? Why Nurix Therapeutics, Inc. (NRIX) is a Great Choice Does Nurix Therapeutics, Inc. (NRIX) have what it takes to be a top stock pick for momentum investors? Let's find out. Zacks ? 3 months ago NRIX +1.33% Nurix Therapeutics, Inc. (NRIX) Reports Q2 Loss, Lags Revenue Estimates Nurix Therapeutics (NRIX) delivered earnings and revenue surprises of -7.58% and 37.51%, respectively, for the quarter ended May 2024. Do the numbers hold clues to what lies ahead for the stock? Zacks ? 3 months ago NRIX +1.33% CELG-RT Nurix Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Provides a Corporate Update Presented positive clinical data at the European Hematology Association Congress supporting a potential best-in-class profile for NX-5948 for the treatment of CLL Strengthened leadership with appointment of Paula G. O’Connor, M.D., as chief medical officer and Pasit Phiasivongsa, Ph.D., as chief technical officer Strengthened financial position ending the quarter with cash and marketable securities of $452.5 million SAN FRANCISCO, July 11, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasda GlobeNewswire ? 3 months ago NRIX +1.33% Nurix Therapeutics to Participate in the UBS Virtual Targeted Protein Degradation (TPD) Day SAN FRANCISCO, July 08, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, will participate in a fireside chat at the UBS Virtual Targeted Protein Degradation (TPD) Day, at 2:30 p.m. ET on Monday, July 15, 2024. The event will be we GlobeNewswire ? 3 months ago NRIX +1.33% Nurix Therapeutics, Inc. (NASDAQ:NRIX) is a favorite amongst institutional investors who own 66% Key Insights Significantly high institutional ownership implies Nurix Therapeutics' stock price is sensitive to their... Simply Wall St. ? 3 months ago NRIX +1.33% Beyond Air, Inc. (XAIR) Reports Q4 Loss, Misses Revenue Estimates Beyond Air (XAIR) delivered earnings and revenue surprises of 23.40% and 33.33%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock? Zacks ? 3 months ago NRIX +1.33% Nurix Therapeutics (NRIX) Surges 20.6%: Is This an Indication of Further Gains? Nurix Therapeutics (NRIX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. Zacks ? 3 months ago NRIX +1.33% OMGA Nurix Therapeutics, With 345% Run, Posts A 'Clear Win' In Leukemia Treatment Nurix posted a "clear win" in leukemia treatment on Monday, but the biotech stock gave back some of its gains. Investor's Business Daily ? 4 months ago NRIX +1.33% Performance Overview Trailing total returns as of 10/18/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return NRIX S&P 500 YTD +142.73% +22.95% 1-Year +312.01% +34.10% 3-Year -13.11% +31.16%
